Fiorentini M T, Fracchia M, Galatola G, Barlotta A, de la Pierre M
Divisione di Gastroenterologia, Ospedale Mauriziano Umberto I di Torino, Italy.
Dig Dis Sci. 1990 Sep;35(9):1180-2. doi: 10.1007/BF01537594.
Therapy with oral 5-aminosalicylic acid for inflammatory bowel disease has been reported as effective and safe. We report two cases of biochemically proven mild acute pancreatitis occurring 2 and 14 days, respectively, after oral 5-aminosalicylic acid therapy was instituted for inflammatory bowel disease. A hypersensitivity mechanism might be involved, owing to possible erratic systemic absorption of the drug. We suggest clinical and biochemical monitoring for patients undergoing oral 5-aminosalicylic acid therapy in order to confirm its possible association with acute pancreatitis and to assess the actual incidence of such an adverse reaction.
口服5-氨基水杨酸治疗炎症性肠病已被报道为有效且安全。我们报告了两例经生化证实的轻度急性胰腺炎病例,分别在为炎症性肠病开始口服5-氨基水杨酸治疗后2天和14天发生。由于药物可能存在不稳定的全身吸收,可能涉及超敏反应机制。我们建议对接受口服5-氨基水杨酸治疗的患者进行临床和生化监测,以确认其与急性胰腺炎的可能关联,并评估这种不良反应的实际发生率。